Does Famciclovir Cause Birth Defects?
Famciclovir, an antiviral used for herpes zoster and genital herpes, crosses the placenta and reaches the fetus. Animal studies show no evidence of teratogenicity (birth defects) at doses up to 3.7 times the human equivalent, but higher doses caused reduced fetal weight and skeletal variations in rats and rabbits. Human data is limited, with no controlled trials in pregnant women; post-marketing reports include rare cases of congenital anomalies, but causality is unproven.[1][2]
Pregnancy Category and FDA Warnings
Famciclovir is FDA Pregnancy Category B: animal reproduction studies show no fetal risk, but no adequate human studies exist. The label advises avoiding use in pregnancy unless benefits outweigh risks, as it converts to penciclovir, which has similar placental transfer. ACOG recommends alternatives like acyclovir for herpes in pregnancy due to more safety data.[1][3]
Evidence from Human Studies and Registries
Small observational studies and herpes pregnancy registries (e.g., Acyclovir Pregnancy Registry) report no increased risk of major malformations with famciclovir exposure in 60+ first-trimester cases—rates match background (2-4%). However, sample sizes are too small for definitive conclusions on subtle effects like neurodevelopment. One study noted minor increases in preterm birth, possibly linked to maternal herpes severity rather than the drug.[2][4]
What Happens with Exposure in Each Trimester?
- First trimester: Lowest data confidence; theoretical DNA polymerase inhibition risk, but no confirmed defects.
- Second/third trimesters: Primarily treats outbreaks; may reduce maternal-to-fetal herpes transmission (5-8% untreated risk), but monitor for neonatal effects like low birth weight.
No long-term developmental follow-up studies exist.[1][5]
Safer Alternatives During Pregnancy
Acyclovir and valacyclovir are preferred (Category B, extensive data showing no malformation risk). They suppress herpes recurrences by 75-90% without harming fetuses. Famciclovir is reserved for cases where oral absorption issues make others ineffective.[3][6]
Breastfeeding and Neonatal Risks
Famciclovir enters breast milk at low levels (penciclovir ~0.4x maternal plasma). Short-term use is generally safe, but monitor infants for diarrhea or lethargy. Pump and discard during outbreaks if neonatal herpes risk is high.[1][2]
Sources
[1]: Famciclovir Prescribing Information (FDA)
[2]: Drugs in Pregnancy and Lactation (Briggs et al.)
[3]: ACOG Guidelines on Herpes in Pregnancy
[4]: Pasternak et al., NEJM 2010 (Antivirals in Pregnancy)
[5]: MotherToBaby Fact Sheet: Famciclovir
[6]: CDC Herpes Treatment Guidelines